Coronavirus disease-19 encephalitis as a differential diagnosis of a cyclosporine related posterior leukoencephalopathy syndrome: A case report.

Q3 Medicine Tunisie Medicale Pub Date : 2024-07-05 DOI:10.62438/tunismed.v102i7.5027
Sanda Mrabet, Achraf Jaziri, Maha Araoud, Dorsaf Zellama, Salma Naija, Sana Ben Amor, Alaa Souissi, Héla Jemni
{"title":"Coronavirus disease-19 encephalitis as a differential diagnosis of a cyclosporine related posterior leukoencephalopathy syndrome: A case report.","authors":"Sanda Mrabet, Achraf Jaziri, Maha Araoud, Dorsaf Zellama, Salma Naija, Sana Ben Amor, Alaa Souissi, Héla Jemni","doi":"10.62438/tunismed.v102i7.5027","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Posterior leukoencephalopathy syndrome (PRES) is a rare neurological disease possibly associated with the use of calcineurin inhibitors like cyclosporine A (CSA). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the outbreak of coronavirus disease 19 (COVID-19) can cause neurological manifestations. We described a case of CSA-related PRES whose diagnosis was difficult due to a concurrent infection with SARS-CoV-2.</p><p><strong>Observation: </strong>The 16-year-old patient was known to have corticosteroid-resistant nephrotic syndrome secondary to minimal change disease. CSA was introduced, and on the fifth day of treatment, the patient presented with seizures followed by fever. Biological and magnetic resonance imaging data were in favor of SARS-CoV-2 encephalitis. Relief of immunosuppression by discontinuation of CSA was decided and the patient was put on anticonvulsants. After being declared cured of COVID-19, which was without other clinical signs, the CSA was reintroduced but the patient presented with seizures the next day. This allowed the physicians to rectify the diagnosis and relate the seizures to a CSA-related PRES.</p><p><strong>Conclusion: </strong>Infection with SARS-CoV-2 could be a differential diagnosis of a PRES related to calcineurin inhibitors.</p>","PeriodicalId":38818,"journal":{"name":"Tunisie Medicale","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358812/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tunisie Medicale","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62438/tunismed.v102i7.5027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Posterior leukoencephalopathy syndrome (PRES) is a rare neurological disease possibly associated with the use of calcineurin inhibitors like cyclosporine A (CSA). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the outbreak of coronavirus disease 19 (COVID-19) can cause neurological manifestations. We described a case of CSA-related PRES whose diagnosis was difficult due to a concurrent infection with SARS-CoV-2.

Observation: The 16-year-old patient was known to have corticosteroid-resistant nephrotic syndrome secondary to minimal change disease. CSA was introduced, and on the fifth day of treatment, the patient presented with seizures followed by fever. Biological and magnetic resonance imaging data were in favor of SARS-CoV-2 encephalitis. Relief of immunosuppression by discontinuation of CSA was decided and the patient was put on anticonvulsants. After being declared cured of COVID-19, which was without other clinical signs, the CSA was reintroduced but the patient presented with seizures the next day. This allowed the physicians to rectify the diagnosis and relate the seizures to a CSA-related PRES.

Conclusion: Infection with SARS-CoV-2 could be a differential diagnosis of a PRES related to calcineurin inhibitors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
冠状病毒病-19脑炎作为环孢素相关后遗白质脑病综合征的鉴别诊断:病例报告。
简介后遗白质脑病综合征(PRES)是一种罕见的神经系统疾病,可能与使用环孢素 A(CSA)等钙神经蛋白抑制剂有关。导致冠状病毒病 19(COVID-19)爆发的严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)可引起神经系统表现。我们描述了一例与 CSA 相关的 PRES 病例,由于同时感染了 SARS-CoV-2,该病例的诊断非常困难:这名 16 岁的患者已知患有皮质类固醇抵抗性肾病综合征,继发于微小病变。患者接受了 CSA 治疗,在治疗的第五天,患者出现癫痫发作,随后发烧。生物和磁共振成像数据均显示为 SARS-CoV-2 脑炎。于是决定停用 CSA 以缓解免疫抑制,并给病人服用抗惊厥药。在被宣布治愈 COVID-19(无其他临床症状)后,重新开始使用 CSA,但患者第二天又出现癫痫发作。这使医生能够更正诊断,将癫痫发作与 CSA 相关的 PRES 联系起来:结论:SARS-CoV-2感染可作为与钙调磷酸酶抑制剂相关的PRES的鉴别诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Tunisie Medicale
Tunisie Medicale Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
72
期刊最新文献
GAIA therapeutic farm: Prospective study on multidisciplinary care efficacy. Iatrogenic risk in elderly patients. Impact of virtual reality on the perception of procedural pain in paediatric oncology. Incidence and risk factors of venous thromboembolism in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Intravenous Leiomyomatosis of the Uterus: An Intriguing Case Revealed through Anatomopathological Examination.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1